Nicoletta Ranallo

Meldola, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins.

DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins.

Journal: Frontiers in endocrinology

Published: April 24, 2026

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management.

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management.

Journal: Journal of neuroendocrinology

Published: June 04, 2025

Treatments and Outcomes in Neuroendocrine Patients Treated with Long-Acting Somatostatin Analogues: An Italian Real-World Propensity Score-Matched Cohort Study.

Treatments and Outcomes in Neuroendocrine Patients Treated with Long-Acting Somatostatin Analogues: An Italian Real-World Propensity Score-Matched Cohort Study.

Journal: Biomedicines

Published: January 15, 2025

Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.

Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.

Journal: Neuroendocrinology

Published: June 12, 2024

First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).

First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).

Journal: Frontiers in immunology

Published: March 21, 2024

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 08, 2024

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 27, 2023

Lipids and adipocytes involvement in tumor progression with a focus on obesity and diet.

Lipids and adipocytes involvement in tumor progression with a focus on obesity and diet.

Journal: Obesity reviews : an official journal of the International Association for the Study of Obesity

Published: October 23, 2023

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.

Journal: Journal of neuro-oncology

Published: April 19, 2023

COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.

COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.

Journal: Endocrine-related cancer

Published: February 23, 2023

Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin.

Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin.

Journal: Cancers

Published: January 06, 2023

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.

Journal: Frontiers in endocrinology

Published: September 15, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026